TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. (E25678) Stock Price

Taisho Pharmaceutical Holdings and its group companies operate across a wide range of business segments. The company primarily engages in two main areas: the Self-Medication business, which researches, develops, manufactures, and sells over-the-counter pharmaceuticals, quasi-drugs, food products, medical devices, and hygiene products; and the Pharmaceutical business, which researches, develops, manufactures, and sells prescription pharmaceuticals.

In the Self-Medication business, the domestic subsidiary Taisho Pharmaceutical Co., Ltd. handles research, development, and sales of over-the-counter pharmaceuticals, quasi-drugs, and food products. Mejiro Kosan Co., Ltd. manages real estate leasing and property management, while Biofermin Pharmaceutical Co., Ltd. develops, manufactures, and sells over-the-counter pharmaceuticals. Overseas subsidiaries, including Taiwan Taisho Pharmaceutical Co., Ltd. and California Taisho Pharmaceutical Co., Ltd., manufacture (through outsourcing) and sell OTC pharmaceuticals and tonic drinks.

In the Pharmaceutical business, Taisho Pharmaceutical Co., Ltd. is responsible for research, development, manufacturing, and sales of prescription pharmaceuticals. Taisho Pharma Co., Ltd. provides information services for prescription pharmaceuticals, while Biofermin Pharmaceutical Co., Ltd. and Tokuhon Co., Ltd. develop, manufacture, and sell prescription pharmaceuticals. Internationally, Taisho R&D USA Inc. handles the development of prescription pharmaceuticals.

Through these operations, the Taisho Pharmaceutical Holdings Group provides a diverse range of health-related products domestically and internationally, offering solutions that address a wide variety of customer needs.

Taisho Pharmaceutical Holdings aims to provide excellent pharmaceuticals, health-related products, information, and services to consumers seeking health and beauty. The company is committed to supporting consumers comprehensively—from health promotion and disease prevention to treatment—and contributing to the realization of a sustainable society.

As a management strategy, the company pursues sustainable growth amid international competition while driving growth in its self-medication and pharmaceutical businesses. This includes building a strong operational foundation. Through its business activities, the company seeks to meet the expectations of consumers, business partners, employees, local communities, and shareholders while pursuing sustainable growth.

In the self-medication business, the company is expanding operations both domestically and internationally. Domestically, it is enhancing the value of existing brands such as the Lipovitan and Pabron series, while newly launching antigen test kits. Internationally, the company is strengthening its presence in Asian and European markets, successfully acquiring locally-rooted brand assets through M&A and brand acquisitions.

In the pharmaceutical business, amid increasing difficulty in drug discovery, the company is focusing on priority areas including orthopedic diseases and metabolic diseases. On the sales front, it is concentrating on maximizing the value of newly launched products. On the research and development front, it is strengthening its pipeline through early regulatory approvals of development compounds and licensing activities.

Taisho Pharmaceutical Holdings is exploring new business opportunities beyond existing business domains and enhancing value creation across the group through agile management decisions and strengthened corporate governance in response to environmental changes.